Developmental therapeutics for inflammatory breast cancer: Biology and translational directions
- PMID: 27926493
- PMCID: PMC5355355
- DOI: 10.18632/oncotarget.13778
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions
Abstract
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, which accounts for approximately 3% of cases of breast malignancies. Diagnosis relies largely on its clinical presentation, and despite a characteristic phenotype, underlying molecular mechanisms are poorly understood. Unique clinical presentation indicates that IBC is a distinct clinical and biological entity when compared to non-IBC. Biological understanding of non-IBC has been extrapolated into IBC and targeted therapies for HER2 positive (HER2+) and hormonal receptor positive non-IBC led to improved patient outcomes in the recent years. This manuscript reviews recent discoveries related to the underlying biology of IBC, clinical progress to date and suggests rational approaches for investigational therapies.
Keywords: immunotherapy; inflammatory breast cancer; targeted therapy.
Conflict of interest statement
The authors declare no potential conflicts of interest
Figures

References
-
- Haagensen CD. Diseases of the female breast. Trans N Engl Obstet Gynecol Soc. 1956;10:141–56. doi: - PubMed
-
- Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22:515–23. doi: 10.1093/annonc/mdq345. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous